292 related articles for article (PubMed ID: 33467196)
1. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
[TBL] [Abstract][Full Text] [Related]
2. Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.
Richard F; van Lier JJ; Roubert B; Haboubi T; Göhring UM; Dürrenberger F
Am J Hematol; 2020 Jan; 95(1):68-77. PubMed ID: 31674058
[TBL] [Abstract][Full Text] [Related]
3. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
[TBL] [Abstract][Full Text] [Related]
4. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD
Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
[TBL] [Abstract][Full Text] [Related]
6. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
[TBL] [Abstract][Full Text] [Related]
8. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G
Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
10. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.
Gardenghi S; Marongiu MF; Ramos P; Guy E; Breda L; Chadburn A; Liu Y; Amariglio N; Rechavi G; Rachmilewitz EA; Breuer W; Cabantchik ZI; Wrighting DM; Andrews NC; de Sousa M; Giardina PJ; Grady RW; Rivella S
Blood; 2007 Jun; 109(11):5027-35. PubMed ID: 17299088
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model.
Garcia-Santos D; Hamdi A; Saxova Z; Fillebeen C; Pantopoulos K; Horvathova M; Ponka P
Blood; 2018 Jan; 131(2):236-246. PubMed ID: 29180398
[TBL] [Abstract][Full Text] [Related]
14. Efficacy And Tolerability Of Oral Iron Chelator, Deferasirox.
Tahir A; Hussain SI; Khan HS; Khalil S; Haider SZ; Lodhi MA
J Ayub Med Coll Abbottabad; 2021; 33(2):207-212. PubMed ID: 34137530
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Chen CH; Shu KH; Yang Y
Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
Dou H; Qin Y; Chen G; Zhao Y
Acta Haematol; 2019; 141(1):32-42. PubMed ID: 30504715
[TBL] [Abstract][Full Text] [Related]
18. Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.
Tanous O; Azulay Y; Halevy R; Dujovny T; Swartz N; Colodner R; Koren A; Levin C
BMC Nephrol; 2021 Dec; 22(1):418. PubMed ID: 34930156
[TBL] [Abstract][Full Text] [Related]
19. Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.
Casu C; Aghajan M; Oikonomidou PR; Guo S; Monia BP; Rivella S
Haematologica; 2016 Jan; 101(1):e8-e11. PubMed ID: 26405152
[No Abstract] [Full Text] [Related]
20. Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: A narrative review.
Babu T; Panachiyil GM; Sebastian J; Ravi MD
Indian J Pharmacol; 2020; 52(6):514-519. PubMed ID: 33666193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
